news
El Financiero
2026-08-19
Moderna and Merck cancer vaccine shows success in melanoma trial
A personalized cancer vaccine from Moderna and Merck demonstrated a reduction in melanoma recurrence, marking a major success in mRNA-based cancer therapies.